Phase 2 N=55 Trial Of NS2359 For The Treatment of Cocaine Dependence
Cocaine Use Disorder
Primary: The Number of Participants Who Achieved Abstinence From Cocaine During the Last Three Weeks of the Trial — 2; 2 participants — p==0.97
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=34 Contour Neurovascular System - European Pre-Market Unruptured Aneurysm
Intracranial Aneurysm
Primary: Primary Safety Endpoint: Percentage of Participants With Death of Any Non-accidental Cause or Major Disabling Stroke Within First 30 Days After Treatment or Major…
Phase 2 N=35 Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis
Scleroderma, Systemic
Primary: Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs) — 8; 3; 24; 1 Participants
N/A N=117 Autologous Bone Marrow Mononuclear Cells in the Combined Treatment of Coronary Heart Disease
Ischemic Heart Disease · Bone Marrow Cells · Coronary Artery Bypass Grafting (CABG)
Primary: Assessment of the Initial Risk of Surgery (EuroScore II). — 1.3; 1.07; 1.02 percent — p=0.24
Phase 4 N=206 Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer
Prostate Cancer
Primary: Time to PSA Progression With 1st Line AAT (TTPP1) — 21.39; 5.78 Months — p=<0.001
N/A N=24 Mobile Motivational Physical Activity Targeted Intervention
Osteoarthritis
Primary: Mixed Effect Model Inferential Estimates of Longitudinal Changes Across 3 Time Points (Baseline, Week 14, Week 19) in Insomnia Severity Index — -1.24 units on a scale
N/A N=188 The CHINA TFNA Study
Femur Fractures
Primary: Successful Fracture Union Rate 24 Weeks After Surgery — 81; 83 Participants
Phase 3 N=554 Preoperative Chlorhexidine Gluconate (CHG) Cloth on Healthy Subjects
Surgery
Primary: Percent Responder Rates (%) of Bacterial Reduction on the Abdomen and Groin — 93; 86; 50; 25 Percent of Sites
Phase 3 N=705 A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Age-Related Macular Degeneration
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) — 6.26; 7.08 letters
N/A N=82 3D Printed Models in Mohs Micrographic Surgery
Mohs Micrographic Surgery
Primary: Percent of Correct and Incorrect Mohs Quiz Responses — 93.25; 85.83; 6.75; 14.17 Percent of quiz responses — p=0.007
Phase 2 N=59 NMRC-M3V-Ad-PfCA Vaccine - Clinical Trial 1
Plasmodium Falciparum
Primary: Part A Dose-Escalation: Number of Participants Who Experienced Any Serious Adverse Events Related To Vaccine Administration — 0; 0 Participants
Phase 2 N=27 Efficacy and Tolerability of STI571 (Imatinib Mesylate) for the Treatment of Fibrosis in Participants With Systemic Sclerosis
Systemic Sclerosis, Scleroderma
Primary: Change From Baseline in Modified Rodnan Skin Score (MRSS) at Each Time Point of Analysis — 25.7; 6.58; 5.97; 8.34 units on a scale
N/A N=658 Regulatory Request NIS in Korea
Diabetes Mellitus, Type 2
Primary: Percentage of Participants With Any Adverse Events — 11.94 Percentage of participants
Phase 3 N=328 CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
Dry Eye Disease
Primary: Change From Baseline in Total Corneal Fluorescein Staining at Day 29 — -2.9; -2.2 score on a scale
Phase 2 N=66 Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms
COVID-19
Primary: Participants With a Disease Control Status Defined as no Disease Progression to Severe. — 30; 26 Participants